Skip to main content
INSMED Inc logo

INSMED Inc — Investor Relations & Filings

Ticker · INSM ISIN · US4576693075 LEI · 529900Q55QAG41CCAC11 US Manufacturing
Open in API
Filings indexed 1,323 across all filing types
Latest filing 2022-07-08 Director's Dealing
Country US United States of America
Listing US INSM

About INSMED Inc

https://insmed.com/

Insmed Incorporated is a global biopharmaceutical company dedicated to developing and commercializing therapies for patients with serious and rare diseases. The company's primary focus is on addressing areas of high unmet medical need. Its marketed product, Arikayce (liposomal amikacin for inhalation), is a treatment for Mycobacterium avium complex (MAC) lung disease. Insmed leverages proprietary technologies, such as its advanced liposomal pulmonary delivery system, to create novel treatments. The company maintains a diverse pipeline of investigational medicines and is actively advancing potential new therapies through various stages of clinical trials.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2022-07-08 English
FORM 4
Director's Dealing
2022-05-25 English
FORM 3
Director's Dealing
2022-05-25 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated May 23, 2022, reporting the appointment of a new Chief Commercial Officer, Mr. Drayton Wise. The content focuses on management changes, including details of the appointment, compensation, and severance arrangements. There is no financial data or report attached, and the primary subject is a change in senior management. According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under Board/Management Information (MANG). Therefore, this document is best classified as MANG with high confidence.
2022-05-23 English
S-8
Capital/Financing Update Classification · 95% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used for registering securities to be offered under employee benefit plans such as stock option plans. It references incorporation by reference of prior filings like 10-K, 10-Q, and 8-K but does not itself contain financial statements or earnings data. The document is a registration statement related to securities issuance under employee plans, not a financial report, earnings release, or management discussion. Therefore, it fits best under the category of Capital/Financing Update (CAP), as it relates to registration of securities for issuance under incentive plans.
2022-05-19 English
FORM 4
Director's Dealing
2022-05-18 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.